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ABSTRACT

An abstract of the thesis of Kimberly J. Lavoie for the Master of Science in Speech
and Hearing Sciences presented February 12,2003.

Title: High frequency Pure Tone Audiometry and High Frequency Distortion Product
Otoacoustic Emissions: A Correlational Analysis.

Previous studies show that pure tone thresholds are strongly correlated with
distortion product otoacoustic emission amplitudes when evaluating the frequency
range from 1 to 8 kHz CAvan & Bonfils, 1993). Little is known about correlations
between these two measures at higher frequencies from 9-16 kHz. This study
compared pure tone thresholds and distortion product otoacoustic emissions
(DPOAEs) in this high frequency range for 29 normal hearing subjects ages 18-30.
Pure tone thresholds were obtained at 250-16 kHz and distortion product otoacoustic
emissions CDPOAE) 2,211-17,675 were measured in the same ears. DPOAE
amplitudes were measured using a constant F11F2 ratio of 1.2, with F2 values ranging
from 2,211-17,675 Hz. Data obtained from 50 ears showed a decline in DPOAE
amplitude with increasing frequency of the F1 and F2 primary stimulus tones.
Behavioral thresholds demonstrated an increase with increasing frequency of the pure
tone stimulus. Pearson r- correlation analysis demonstrated a weak relationship
between measures. Further investigation revealed that equipment variables prevented
accurate readings.
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High Frequency Correlations 1

High frequency pure tone audiometry and high frequency DPOAE's

Current methods of obtaining auditory thresholds include both behavioral and
physiological measurements of hearing sensitivity. Standard behavioral hearing tests
include pure tone audiometry, measuring pure tone thresholds from 250-8000 Hz.
Researchers have discovered that information about hearing sensitivity at frequencies
beyond this standard range may provide valuable information for clinical and research
applications (Fausti, Frey, Erickson, Rappaport, & Cleary, 1979). One application of
high frequency audiometry is for early detection of ototoxic damage (Dreschler, Hulst,
Tange, & Urbanus, 1989).
A standard physiological method of obtaining audiometric information is
through the use of otoacoustic emissions. Otoacoustic emissions are an indirect
physical measurement of the outer hair cell function ofthe cochlea, and are not
dependent on a behavioral response (Hall, 2000). There are four types of otoacoustic
emissions: Spontaneous (SOAE), Stimulus Frequency (SFOAE), Transient (TEOAE),
and Distortion Product otoacoustic emissions (DPOAE). Two types, transient, and
distortion product otoacoustic emissions, are applied clinically (Hall, 2000). An
example of the application of otoacoustic emissions is monitoring for the ototoxic
effects of medications (Stavroulaki, Apostopoulos, Segas, Tsakanikos, &
Adamopoulos, 2001).
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Several medications prescribed are known to cause auditory and vestibular
dysfunction. Categories of ototoxic medications may include anti-inflammatory drugs,
amino glycoside antibiotics, loop diuretics, antimalarials, chemotherapeutic agents,
and ototopical medications (Jordan & Roland, 2000).
The effects of medications are thought to be expressed throughout many areas
of the auditory system. Areas affected may include the outer hair cells in the mid turn
and basal turn organ of Corti, and neurons in the spiral ganglion (Gabaizadeh et aI.,
1997). The stria vascularis may also demonstrate severe degenerative changes (Hulst,
Dreschler, and Urbanus, 1988). At the cellular level, it is theorized that medications
can result in an increase of intracellular calcium, thereby adversely affecting cell
membranes, and ultimately resulting in magnesium deficiency (Cevette, Drew, Webb
and Marion, 2000).
Ototoxic damage to the auditory system may manifest itself clinically as an
initial bilateral high frequency sensorineural hearing loss, which may progress to a loss
in sensitivity at all frequencies (Jerger & Jerger, 1981). This dysfunction is most often
identified through the application of pure tone audiometry.
Many studies have evaluated changes in the auditory system with pure tone
audiometry in patients using ototoxic medications. In one such study measuring from
250-8000 Hz for patients undergoing carboplatin chemotherapy administered in
conjunction with osmotic opening of the blood-brain barrier, post treatment auditory
threshold shifts were identified at 4000 and 8000 Hz (Doolittle et aI., 2001). This
identification of changes in auditory thresholds supported the need for prospective
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monitoring of frequencies higher than 8000 Hz for patients enrolled in platinum based
chemotherapy clinical trials.
When comparing the detectability for ototoxic damage between low frequency
and high frequency pure tone audiometry, a 1989 study by Dreschler et aI. (1989)
found that 34-77% of ears with ototoxic damage were discovered in an earlier stage
when using high frequency audiometry. This study also concluded high frequency
damage is present earlier than low frequency damage, with 12000 and 14000 Hz being
the best test frequencies for the detection of ototoxicity (Dreschler et aI., 1989).
Conventional and high frequency pure tone audiometry have been applied in
case studies of patients receiving cisplatin chemotherapy (Fausti, Schechter,
Rappaport, Frey & Mass, 1984). Significant changes in consecutive high frequency
thresholds were revealed in eight of thirteen patients. When comparing low and high
frequency audiometric configurations, it was found that the magnitude of change was
greater in the high frequency range of 8000 Hz- 20000 Hz (Fausti et aI., 1984)
Many studies have not only applied conventional audiometry to the evaluation
of patients using ototoxic medications, but have added otoacoustic emissions to their
regimen as well. Because the presence of an evoked otoacoustic emission is correlated
with normal to near normal hearing thresholds, emissions can reflect the state of the
cochlea (Avan & Bonfils, 1993). As objective indicators of auditory function,
emissions are not affected by extraneous influences; such as inattentiveness
(Lonsbury-Martin, Whitehead, & Martin, 1991) therefore medically compromised
patients can provide reliable responses despite their state of health.
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In a 1998 study of 12 children with a mean age of7.8 years, transient evoked
otoacoustic emissions (TEOAE's) from 1000-5000 Hz were measured and compared
to behavioral thresholds before and after a cisplatin chemotherapy regimen (Allen et
aI., 1998). Consistent with the literature (Doolittle et aI., 2001), hearing loss of greater
than 25 dB HL occurred in 81 % of participants in this study at levels higher than 4000
Hz. When TEOAE reproducibility was compared with pure tone thresholds, it was
found that the emission amplitudes correlated highly with pure tone audiometry
findings.
When comparing TEOAE's, DPOAE's and pure tone audiometry in a pediatric
oncology population undergoing cisplatin chemotherapy (Stavroulaki et aI., 2001) it
was found that distortion product DP grams (a method of profiling distortion product
frequency analysis) are a more sensitive indicator of cochlear dysfunction than
TEOAE's. This study further revealed statistically significant reductions in the DP
.gram amplitudes in patient's ears with normal pure tone thresholds at 3000 Hz. The
authors concluded that DPOAE's are more sensitive than TEOAE's and/or pure tone
audiometry as ototoxicity screening tools.
DPOAE's have thus been shown to be a useful objective test in screening for
ototoxic medications, and high frequency pure tone audiometry has been shown to be
an effective behavioral method of evaluating auditory function in ototoxicity
monitoring. To date there have been no studies examining the correlation high
frequency behavioral pure tone thresholds and high frequency otoacoustic emissions.
Exploring the relationship between these two measurements in a normal hearing
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population might prove useful for establishing baselines to measure the high frequency
threshold changes that patients may encounter with ototoxic medications. The purpose
of this study is to evaluate the relationship between high frequency pure tone
audiometric thresholds, and high frequency DPOAE amplitudes. Behavioral thresholds
will be measured at test frequencies from 250-16,000 Hz in a group of normal hearing
persons. High frequency DPOAE's will be obtained in this same group from 1810
17675.
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REVIEW OF THE LITERATURE
High Frequency pure tone audiometry
In 1979, a system for evaluating auditory thresholds from 8000-20000 Hz was
developed to evaluate changes in high frequency hearing sensitivity due to ototoxic
agents and noise exposure (Fausti et aI., 1979). This system employs the use of a high
output, low noise amplifier/filter for high fidelity, and an earphone that includes a
ceramic diaphragm to provide a relatively flat response from 8000-20000 Hz (Fausti,
Rappaport, Schechter, & Frey, 1982).
This system for evaluating hearing sensitivity includes obtaining threshold
information in the conventional frequencies from 250-8000 Hz by applying the
standard audiometric procedure of Hughson-Westlake technique in 5 dB increments.
Second, high frequency thresholds are then obtained from 8000-20000 Hz, using a 2
dB bracketing tectmique (Fausti et aI., 1984).
When recruiting participants to assess this high frequency measurement
system, a survey evaluating frequencies above 12000 Hz found applicants to have
highly variable hearing sensitivity on average, with medical history not accounting for
the differences in hearing thresholds. The 21 participants from this survey
demonstrated mean thresholds from 500-12000 Hz to be less than or equal to 20 dB
SPL, rising slightly to 35 dB SPL at 17000 Hz, then increasing to 82 dB SPL at 20000
Hz (Fausti et aI., 1979).
Application of this high frequency system discovered participants to have a
progressive sloping response from 8000-20000 Hz. Mean between test differences for

High Frequency Correlations 7
high frequency thresholds revealed no variations in thresholds greater than 4 dB
(Fausti et aI., 1979). Hulst et aI. (1985) performed a similar with results consistent
with Fausti et.aI. In evaluating 180 audiograms, standard deviation of repeated
measurements was found to be within 4.3 dB HL from 250-20000 Hz.
Sites of ototoxic damage
The exact mechanisms affected by cisplatin are not known (Allen et aI., 1998)
however; outer hair cell degeneration is a consistently reported side effect of patients
undergoing cisplatin chemotherapy. Research evaluating the mechanisms involved in
cisplatin ototoxicity on outer hair cells (e.g., McAlpine & Brownstone, 1990) suggests
the ototoxic effects of cisplatin specifically disrupt the mechano-electrical transduction
process of the outer hair cells. This causes a reduction in hair cell receptor current
and thus subsequent hearing loss (McAlpine et aI., 1990).
In comparing which frequencies are damaged by cisplatin ototoxicity, Mc
Alpine et aI. (1990) discovered that "there are no differences in the susceptibility of
high and low frequency regions of the cochlea, but that the higher frequency regions
are more permeable to cisplatin." Studies evaluating the audiometric configuration of
cisplatin ototoxicity demonstrate these effects in that the first area of the cochlea to
suffer hearing loss is the high frequency region (Fausti et aI., 1984; Dreschler, Hulst,
Tange & Urbanus, 1985).
Other areas reportedly affected by ototoxic agents are the mid turn, and basal
turn organ of Corti and the spiral ganglion. In animal studies analyzing the
otoprotective effects ofD-methionine, (Gabaizadeh et al., 1997) researchers exposed
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the midturn, basal turn organ of Corti and whole spiral ganglion samples of Wistar rat
pups to cisplatin. When applying a concentration of 6 Ilg Iml of cisplatin without an
otoprotectant, damage to the spiral ganglion resulted in no survival of auditory
neurons. Exposing midtum and basal turn organ of Corti samples to 4 Ilg/ml resulted
in significantly lower hair cell densities than when compared to unexposed samples,
and stereocilia bundle indices were reduced significantly for both outer and inner hair
cells (Gabaizadeh et aI., 1997).
Cisplatin and carboplatin chemotherapy agents
Cisplatin is a potent antineoplastic agent effective against a variety of tumors
(McAlpine et aI., 1990). Cisplatin has exhibited a broad spectrum of activity against
epithelial cancers and has become the "foundation of curative regimens for testicular
and ovarian cancers". It has also demonstrated significant activity against cancers of
the head and neck, esophagus, lung, bladder, cervix, and endometrium (Go et aI.,
1999).
Various toxic side effects have been observed after cisplatin treatment,
including severe renal, neurologic, cytotoxic and emetogenic effects (Go et al. 1999).
Other associated side effects may also include myelosuppression, gastrointestinal
dysfunction, ototoxicity, and vestibulotoxicity (Hulst et aI., 1988).
In 1981 carboplatin, an analog of cisplatin was introduced to circumvent some
of the toxicities of cisplatin. Both are platinum complexes, but their compounds differ
in that cisplatin contains two chloride "leaving" groups and carboplatin has a
cyclobutane group (Go et aI., 1999). Because carboplatin and cisplatin share a similar
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structure, they undergo the same chemical reactions and both target DNA as their
major cytotoxic target. Concentration of the two drugs vary however, in that
carboplatin requires 10 times higher drug concentration and longer incubation time to
induce the same degree of change on DNA (Go et aI., 1999).
It has been revealed that carboplatin displays less nephrotoxicity, ototoxicity,
and neurotoxicity than cisplatin (as cited in Neuwelt et al., 1998; Go et aI., 1999)
Renal impainnent is rare under carboplatin chemotherapy, except at extremely high
doses (Hulst et aI., 1988) and carboplatin nausea and vomiting are less severe and
frequent as compared to cisplatin (Go et al., 1999).
It is believed that carboplatin and cisplatin may have different sites of damage
to the auditory system. It has been established that carboplatin exerts toxic effects on
inner hair cell function, whereas cisplatin's effects are exhibited on outer hair cell
function (Hoffstetter, Ding, Powers, & Salvi, 1997). These findings may have a
significant impact on threshold monitoring, in that DPOAE's are independent of inner
hair cell function (Hall, 2000). DPOAE's rely on functional outer hair cells for
auditory threshold monitoring. According to Hall (2000), clinical protocols in
monitoring for carboplatin ototoxicity should include measures of inner hair cell
function such as pure tone audiometry or auditory brain stem response.
Use of otoprotectants
Due to the nephrotoxic, neurotoxic, myelosuppressive, and ototoxic
mechanisms of cisplatin chemotherapy (Go et aI., 1999) researchers have evaluated the
effects of using chemoprotectants in combination with platinum chemotherapy agents
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in clinical and pre-clinical settings (Neuwelt et aI., 1996; Gabaizadeh et aI., 1997;
Neuwelt et al., 1998; Campbell et ai. 1998; Doolittle et aI, 2001). A potential
chemoprotectant against carboplatin-induced ototoxicity is delayed high dose sodium
thiosulfate (STS). STS is effective as an otoprotectant when carboplatin is
administered in conjunction with osmotic opening of the blood-brain barrier (Doolittle
et aI., 2001). Agents that may provide protection against cisplatin-induced ototoxicity
may include D-:-methionine (Campbell et. al, 1997). The mechanism ofSTS protection
against carboplatin ototoxicity is unclear. It is currently theorized that the cochlea may
act similar to the kidney to concentrate STS in the perilymph or endolymph. High
concentrations of STS may act to inactivate carboplatin at the site of cochlear damage
(Neuwelt et al. 1996). This inactivation is thought to occur through the chemical
reaction of the thiol binding to the electrophile platinum, thus rendering the platinum
inactive (Neuwelt et aI., 1998, Doolittle et al, 2001).
Animal studies evaluating carboplatin ototoxicity in a guinea pig model
demonstrated protection when STS was given up to eight hours subsequent to
carboplatin (Neuwelt et al., 1996). Determination of the effect of STS on carboplatin
induced ototoxicity was by electrophysiological measurements and cochlear hair cell
count (Neuwelt et al., 1996).
Studies evaluating the efficacy of high dose STS in patients with malignant
brain tumors, noted what appeared to be a preservation of hearing (Neuwelt et aI.,
1998). In Neuwelt et al. 's study (1998), twenty nine patients ranging from 2-63 years
of age treated with carboplatin followed by one dose of STS, were compared to a
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historical group of 19 patients treated with carboplatin that did not receive STS.
Patients with excellent baseline hearing (thresholds < 20 dB HL in the frequency range
of 250-8000 Hz) showed little change in high frequency thresholds with a mean loss of
8

±

5.6 dB after the first carboplatin followed by STS treatment. In comparison,

patients in the (no STS) historical group with excellent baseline hearing thresholds,
demonstrated a mean hearing loss of30.0

±

8.4 dB after the first carboplatin treatment

(Neuwelt et aI., 1998).
This 1998 study further demonstrated that 50% of patients with impaired
baseline hearing (thresholds> 20 dB HL in the frequency range of250-8000 Hz)
developed an additional 20 dB threshold shift, despite treatment with one dose of STS
(Neuwelt et al. 1998). Because of this finding, the treatment regimen was altered.
Patients with impaired baseline hearing thereafter received a second dose of STS, 6
hours following carboplatin treatment (Doolittle et aI., 2001).
In a more recent study, audiologic data from patients who received STS two (or
two and six) hours after carboplatin, and patients who received STS four (or four and
eight) hours after carboplatin, were compared with the historical (no STS) group.
Spearman rank correlation coefficients showed decreased rates of ototoxicity, with
greater decay in STS (Doolittle et aI., 2001).
Otoacoustic Emissions
Otoacoustic emissions (OAE's) are the result ofbiomechanical activity
associated with normally functioning outer hair cells. This motility produces a signal
within the cochlea that is transmitted through the middle ear and ossicles. The signal is
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then measured with a microphone inserted into the ear canal (Gelfand, 1997). Because
OAEs can reflect the state of the cochlea, they are applied clinically to provide an
objective measure of auditory sensitivity (Hall, 2000). There are two general
categories of otoacoustic emissions, spontaneous and evoked.
Spontaneous otoacoustic emissions (SOAEs) are emissions that occur in the
absence of external stimuli. They consist of energies at one or more frequencies
emitted by the normal ear (Hall, 2000). SOAEs are most commonly detected in the
1000-2000 Hz region where reverse transmission through the middle ear is most
efficient (Kemp, 1986). Clinical application of SOAEs are limited, as they can be
detected in only 50% of ears with normal hearing, with a genetic preference for
females, they have variable amplitudes over time, and frequencies at which they occur
are limited (Lonsbury-Martin et aI., 1991).
Evoked otoacoustic emissions are emissions that occur in response to
presentation of an acoustic stimulus. These emissions can be further categorized into
three subtypes according to the stimuli used to elicit them. Transient evoked emissions
(TEOAEs) are elicited by a click, or toneburst; stimulus frequency (SFOAEs) are
evoked by a single continuous pure tone; and acoustic distortion products (DPOAEs)
are generated in response to two continuous pure tones separated using a prescribed
frequency difference (Lonsbury-Martin et aI., 1991).
SFOAEs are emissions that are evoked using a constant pure tone stimulus
presented at a low intensity level swept or changed slowly across a region of
frequencies (Hall, 2000). SFOAEs are more difficult to analyze than other types of
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emissions, because it is necessary to separate the SFOAE from the stimulus tone that is
simultaneously present in the ear canal, and is larger than the emission (Lonsbury
Martin et.al. 1991). There are currently no available devices for recording SFOAEs;
therefore they are the least studied experimentally, and clinically (Hall, 2000).
TEOAEs are acoustical signals emitted by outer hair cells of the cochlea on
presentation of transient stimuli, such as clicks, or tone bursts (Ferguson, Smith,
Davis, & Lutman, 2000). TEOAE's are a waveform that is generated in the cochlea,
and detected in the ear canal several milliseconds following presentation of a stimulus
(Gelfand, 1997). The average latency, or time between waveforms is typically 5-20
milliseconds; time averages tend to decrease with increase in OAE frequency. Spectral
analysis of these waveforms can provide frequency specific information across the
frequency region from 0-5000 Hz (Gelfand, 1997).
Click evoked emissions, such as TEOAE's are thought to reflect the presence
of outer hair cell function of the cochlea. When sensitivity tuning of the inner ear is
impaired within a certain frequency range, spectral components of the TEOAE within
that same frequency range are expected to be altered (Avan, Elbez, & Bonfils, 1997).
This phenomenon supports the clinical utility of TEOAEs in monitoring the state of
the cochlea in areas such as newborn infant hearing screening and ototoxicity
monitoring (Allen et al, 1998).
DPOAEs are emissions that are elicited by the simultaneous presentation of
two pure tones, called primaries, closely spaced in frequency. The two primaries
activate the cochlea in the same region of the basilar membrane, but due to nonlinear
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properties of a healthy cochlea, a third combination tone is generated in the frequency
region where the two primary frequencies overlap. This is combination tone called an
acoustic distortion product (Hall, 2000).
The strongest DPOAE in human ears occurs at the cubic difference frequency,
2f1-f2, in which f1 represents the lower frequency stimulus, and f2 represents the
higher frequency primary (Lonsbury-Martin et aI., 1991). DPOAE amplitudes may
vary with the level of the primary tones, as an increase in level of the primaries results
in an increase emission size (Gelfand, 1997).
Research supports that DPOAE amplitudes provide information as to the
frequency specificity of the cochlea (Avan et aI, 1993; Moulin, Bera & Collet, 1994).
When analyzing DPOAE amplitudes elicited by low frequency primaries, researchers
have found significant correlations with auditory thresholds at the mean frequencies of
the primary tones.
DPOAEs can be measured using two methods; a DPOAE audiogram, which
shows DPOAE amplitude as a function of the geometric mean (generation site) of the
two frequencies, or an input/output function, which measures DPOAE amplitude as a
function of stimulus level at a given frequency (Lonsbury-Martin, et aI, 1991).
Because of their high sensitivity, reliability, an~ objectivity, DPOAEs are used
routinely as a measure of hearing sensitivity not only for patients using ototoxic
medications, but for patients unable to perform behavioral testing, newborn and infant
testing, testing persons with multiple disabilities, and malingerers (Stavroulaki et aI,
2001).
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METHODS
Participants
Twenty nine students from Portland State University volunteered to participate
in this study. To be eligible for inclusion, participants were between 18-30 years of
age at the time of enrollment in this study. Participants had normal hearing sensitivity
at audiometric test frequencies from 250-8000 Hz. Criteria for exclusion from this
study included hearing thresholds above 20 dB HL from 250-8000 Hz, the absence of
otoacoustic emissions from 2000-16000 Hz, or history of significant ear disease or
significant noise exposure.
Volunteers were recruited by flyers posted in hallways at Portland State
University, and by announcement in Speech and Hearing science classrooms.
Volunteers were instructed to register for participation bye-mail or phone.
MaterialslInstrumentation
Testing was performed at the Children's Developmental Rehabilitation Center
(CDRC) at Doernbecher Children's Hospital. Following a brief otoscopic evaluation,
tympanometry was performed using a Orason-Stadler OSI 33 middle ear acoustic
analyzer. Middle ear assessment was made using a Orason-Stadler OSI single use
silicon probe tip, with a 226 Hz probe tone. Following tympanometry, DPOAE's were
measured in a double walled acoustic chamber at CDRC to ensure an adequately low
noise floor. An Etymotic Research (ER 2) transducer was used to obtain DPOAE's.
An Intelligent Hearing Systems Smart OAE program was used to acquire emissions
from 1810-17675 Hz.
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A daily biological calibration of the audiometer was performed to ensure
adequate output before testing began. An exhaustive calibration was performed on the
audiometer prior to the initiation of the study_ DPOAE calibration in a 1 cc coupler
was performed to confmn adequate transducer linearity prior to data collection. No
significant 2F 1-F2 components at any of the primary frequency combinations. The
DPOAE microphone was calibrated using a within the ear approach measurements on
each individual prior to obtaining measurements, according to the manufacturers
recommendations.
L2 and L1levels were set to 65 dB and 55 dB SPL. The F11F2 ratio was set at
the default setting of 1.2 (Hall, 2001).
Table 1. F1 and F2 primary stimulus tones
Frequency combination

Fl,Hz

F2,Hz

1

1810

2211

2

2152

2631

3

2563

3120

4

3042

3717

5

3619

4421

6

4304

5253

7

5125

6250

8

6094

7434

9

7238

8832

10

8617

10505
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(Table 1 continued)
11

10241

12500

12

12178

14858

13

14486

17675

All audiometric testing was conducted within an Acoustic Systems double
walled acoustic chamber. Pure tone thresholds were obtained using an Interacoustics
AC 40 clinical· audiometer. Thresholds were obtained from 250 through 8000 Hz
under TDH 39P headphones. High frequency thresholds from 9000-20000 Hz were
obtained using Sennheiser HDA 200 headphones. Using a technique introduced by
Fausti et al. (1984), standard audiologic techniques were employed to obtain
thresholds from 250-8000 Hz, and a modified Hughson-Westlake technique in 2 dB
increments were used to obtain pure tone thresholds from 8000- 20000 Hz.
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RESULTS
High frequency DPOAEs and pure tone thresholds were collected from 29
participants. This yielded information on these two types of measurements from a
total of 50 ears.
Examples ofDPOAE amplitudes recorded from one subject are given in figure
1A. Each plot shows amplitude of sound recorded in the ear canal as a function of
frequency. Two tones were presented to this subject's ears. The Fl primary was
presented at 1810Hz, stimulating at a level of 65 dB SPL. The F2 primary was
presented at 2211 Hz. The amplitude of the F2 stimulus was 55 dB SPL. These two
tones resulted in a distortion product at a frequency of2F1-F2, which in this case was
1409 Hz. The measured amplitude was 16 dB SPL
Figure 1B is a graph of an acoustic distortion product generated with higher
frequency primaries on the same subject. The Fl primary was presented at 5125 Hz at
a level of 65 dB SPL. The F2 stimulus was presented at 6250 Hz. The F2 intensity
was 55 dB SPL. When using 5125 and 6250 as the two primaries, this resulted in a
2FI-F2 frequency of 4001 Hz. The amplitude of the DPOAE was 8 dB SPL. As the
stimulus frequency increases above 2000 Hz, the distortion product amplitudes are
expected to reduce (Hall, 2000). The difference between the amplitude of the DPOAE
between figures 1 and 2 was 8 dB.
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Figure 1C is a graph of an acoustic distortion product at the high frequency
region (base) of the basilar membrane. The Fl primary was presented at 12178 Hz.
The amplitude was 65 dB SPL. The F2 primary was presented at 14858 Hz, with an
intensity level of 55 dB SPL. When using 12178 and 14858 as the two primaries, this
resulted in a 2FI-Fl frequency of 9498 Hz, with an amplitude of2 dB SPL.
Figure 2 gives 2FI-F2 distortion product amplitude as a function ofF2
frequency for one subject. Thirteen DPOAE combinations were measured with F2
frequencies from 2211 to 17675 Hz. The frequency ratio ofF2 to Fl for each of the
primaries was 1.22. This plot shows all DP emissions measured for all primaries
presented to each ear. The shaded area on the graph represents the noise floor during
testing. This measure varied with each subject, but in this case was below -10 dB
SPL. As demonstrated in figure 2, distortion product amplitude tend to decrease with
increasing frequency.
In Figure 3 distortion product amplitude is plotted as a function of F2
Frequency for all subjects. As with the individual data in Fig. 2, the group data in Fig.
3 tend to show a decline in DP level with increasing frequency. The mean amplitude
from 2211-3717 Hz was 5.7 dB SPL, the mean amplitude from 4421-8832 Hz was 1.4
dB SPL, and the mean amplitude from 10505-17675 Hz was -1 dB SPL. The
amplitude range throughout the frequency spectrum from 2211 to 17675 Hz was an
average of27 dB SPL from 2211-3717 Hz, an average range of27 dB SPL from 4421
8832 Hz, and an average range of32 dB SPL from 10505-17675 Hz. Thus amplitude
variability appears to be similar across frequencies.
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Fig 2. Distortion product amplitude as a function of F2 frequency in kHz. The noise
floor across the frequency spectrum is depicted by the shaded area. These data are
from one ear.
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Behavioral thresholds are given in Figure 4 where pure tone thresholds are
plotted as a function of frequency for all subjects. The most notable effect here is the
increase in pure tone thresholds with increasing frequency. Mean thresholds from
250-3000 Hz were 7 dB HL. Mean thresholds from 4000-9000 Hz were 18 dB HL,
and 32 dB HL from 10000-16000 Hz. A range of 17 dB was found in thresholds from
250-3000 Hz, a 37 dB range from 4000-9000 Hz, and a 70 dB range was illustrated
from 10000 to 16000 Hz. Thus thresholds have the greatest variability in the high
frequencies.
The relationship between behavioral thresholds and DPOAE amplitude
between subjects was explored by conducting a Pearson r correlation analysis at each
frequency. The results of this analysis are given in Table 2. A negative relationship
between variables was found in 10 of the 14 bivariate correlations. The Pearson r
values had a range of -.032 to -.46. The remaining 4 correlations had a positive value,
with a range of .06 to .18 indicating a weak positive correlation for these measures.
Two of the bivariate correlations, 12000 and 14000 Hz were found to be
significant at the .05 level. One frequency, 4000 Hz, was found to be significant at the
.01 level, with an r-value = -.461, indicating a moderate negative correlation.
Table 2 displays the analysis of bivariate correlations for each frequency,
including the Pearson-r correlation value and significance:

Fig 4

120
100

..J

I

A

x

80

"
en

A

m 60
,;

x

"

"0

.c
co

A.

40

!

.c
I

. •+ ••
•• •• .•.
• •

.OF: -

20 _::t.:

I»

••
••
••.

Ii
'
"
.• ...
••
It
lC

•

III

~

I
I I

I

II
I

,i
i•
I

)(

::r=

i

"Tj

(j

-20
0

2000

4000

6000

8000

10000

12000

Frequency, Hz

Fig 4. Pure tone thresholds in dB SPL as a function of frequency for all subjects

14000

16000

18000

1
(j

o
=1
(l)

a~.
N

C\

High Frequency Correlations 27
Table 2. Pearson r correlation analysis
Frequency

Pearson r

Significance (2-tailed)

PT 2000
DP 2361

-.18

.217

PT 3000
DP 3171

-.099

.499

PT 4000
DP 4421

-.461

.001

PT 6000
DP 6250

-.195

.180

PT 8000
DP 8832

-.118

.420

PT 9000
DP 10505

.183

.208

PT 10000
DP 10505

.067

.646

PT 11200
DP 10505

-.035

.812

PT 12500
DP 12500

-.302

.035

PT 14000
DP14858

-.358

.012

PT 16000
DP 14858

-.282

.049

PT 16000
DP17675

.086

.558
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The scatter plots in figure 5A, 5B, and 5C illustrate the relationship between
the objective and sUbjective measurements of hearing sensitivity for all subjects at the
three frequencies with high correlation. If the variables are correlated as suspected, a
diffuse clustering of data points spread around a downward sloping pattern is
expected.
Figure 5A is a scatter plot that displays 4000 Hz pure tone thresholds as a
function of 4421 Hz DPOAE amplitudes. Each data point on the graph represents a
subject response. Figure 5B is a scatter plot that displays the relationships of the
12500 Hz pure tone thresholds and 12500 Hz DPOAE amplitudes in all SUbjects.
Figure 5C is a scatter plot that displays 14858 DPOAE amplitudes and 14000 Hz pure
tone thresholds in all subjects. The correlations between the two measures therefore
appear to be weak.
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Fig SA. A scatter plot illustrating the relationship between 4,000 Hz pure tone and DP
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data points is revealed.
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DISCUSSION
The aim of this study was to evaluate relationship between High frequency
pure tone thresholds and High frequency DPOAE's. Data obtained from 50 ears
showed a decline in DPOAE amplitude with increasing frequencies of the primaries.
This trend is consistent with the findings, as stimulus frequency increases above 2000
Hz, a progressive reduction of DP amplitude for higher frequency stimuli were
recorded when the fl/f2 ratio is kept at 1.22 (Hall, 2000). The present study indicates
that the decline continues to F2 values as high as 17,675 Hz. Our data also
demonstrated an increase in behavioral thresholds with increasing frequency. This is
consistent with the findings of Fausti et aI., 1979, who showed that thresholds for
normal hearing individuals increase with test tone frequencies from 8000-20000 Hz.
The literature has established significant correlations between DPOAEs and
pure tone audiometry when evaluating the frequency range from 250-8000 Hz (Avan
et.al, 1993; Moulin, Bera & Collet, 1994). Our data show a relatively poor correlation
between the two types of measures within this range of frequencies and for frequencies
above 8000 Hz. Possible reasons for the discrepancy in our findings are discussed
below.
An inherent problem with behavioral pure tone thresholds, is the fact that they
are a subjective measurement at risk to variability. When performing a Pearson r
correlation analysis between repeated measures, all thresholds were found to have a
high statistical significance, with an r-value of at least .905 for all frequencies tested
from 9000 through 16000 Hz. This indicates a high level of reproducibility between
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repeated measures. The range of high frequency thresholds was found to be within the
clinically acceptable range of ± 10 dB SPL for repeated thresholds (Frank et.al., 1991).
It is therefore unlikely that the low correlation was due to poor reliability of our
behavioral thresholds.
Repeated measures were not performed on OAEs because they are generally
not subject to patient variability, so an evaluation of equipment was performed. The
Intelligent Hearing Systems (IHS) is the only commercially available device capable of
measuring high frequency DPOAEs for a clinical setting. There are currently no ANSI
standards for high frequency measurements, so protocols and calibrations were
performed using the manufacturer's recommendations with the software and probe tips
recommended by IHS.
As outlined in the methods section, measurement of the transducer output
using a 1 cc coupler was performed prior to data collection to evaluate sthnulus purity.
Emissions should not exist in a hard walled cavity if the transduction system is linear.
We found that there were no significant distortion products that were generated by the
transducer, so we therefore assumed that the system was linear. However, when a
similar check was made following data collection, significant DPOAE amplitudes
were recorded across the frequency spectrum from 2211 to 17675 Hz, with amplitudes
ranging from -13 to 10 dB SPL. This suggests that at some point during data
collection the system may have become nonlinear.
Two possible explanations of this are standing waves and electrical
interference. Standing waves are cancellations and reinforcements of sound waves due
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to reflections or interactions between the stimulus and tympanic membrane (Siegel,
1994). Standing waves can be averaged into amplitude measurements, causing the
response to be underestimated or overestimated in interpretation.
Even when a transducer is designed for optimal conditions, a strong input
signal can drive a transducer to saturation. When saturation occurs, there will be
distortion of the output waveform, so that it will not have the same shape as the input
waveform (Gibilisco, 1993). However, our transducer output was only 65 dB SPL,
while the standard output values are acceptable up to 75 dB SPL without driving the
transducer into saturation. Therefore, transducer saturation was most likely not a
factor.
Due to the fact that there was change in transducer output calibration measures
between initiation and completion of the study, this most likely compromised our data
accuracy. Since our Intelligent Hearing Systems equipment was producing artifacts,
caution should be used that emissions measured are actual measurements and are not
artifacts.
High frequency OAE equipment should come equipped with a fool proof
method of calibration. It is recommended that future protocols include a daily coupler
calibration in addition to an in-the-ear calibration measure before acquiring data on
each subj ect.
High frequency DPOAE's and high frequency pure tone audiometry should be
used in future studies to evaluate correlational relationships for use in ototoxicity
monitoring with different age groups. With properly functioning equipment, this
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research will provide valuable information to the medical and research communities.
Other investigations could include a correlational analysis on a hearing impaired
population, without adjusting protocols performed in our study. DPOAEs would not
be present with hearing thresholds poorer than 35 dB HL. Significant DPOAE
amplitudes on this population would provide evidence as to the presence of standing
waves or electrical interference.
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